🧫
AAV-LRRK2 Gene Therapy IND-Enabling Study Design
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-lrrk2-aa
🧫 Experiment Protocol
Clinical
Metadata
| experiment_type | clinical |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.899189Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['AAV'], 'diseases': ["Parkinson's Disease"]} |
| model_system | human |
| summary | # AAV-LRRK2 Gene Therapy IND-Enabling Study Design ## Background and Rationale Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in |
| replication_status | replicated |
| methodology_notes | Phase 1: Manufacturing and analytical development (Months 1-6). Produce clinical-grade AAV-LRRK2 vector using established GMP protocols. Conduct comprehensive analytical characterization including vec |
| primary_outcome | Validate AAV-LRRK2 Gene Therapy IND-Enabling Study Design |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.899194'} |
🌍 Provenance Graph
10 nodes, 38 edges
derives from (16)
...and 11 more
Linked Artifacts (1474)